Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
KTTA vs ENSC: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
KTTA Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 6–4 Matrix Metrics)
KTTA Overall Winner
6-Pillar Tally: KTTA 2 – 2 ENSC (2 Tie)
Matrix Metrics: KTTA 6 – 4 ENSC
As of Nov 20, 2026, Pasithea Therapeutics Corp. (KTTA) is the stronger overall head-to-head candidate over Ensysce Biosciences, Inc. (ENSC) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). KTTA carries a Unified Composite Score of 42.1/100 (HOLD) at $0.48 (N/M Forward P/E, 0.0% operating margin), whereas ENSC carries 53.4/100 (HOLD) at $0.36 (0.8x Forward P/E, -281.3% operating margin).
- Composite vs. Pillar Nuance: While ENSC currently prints a higher short-term Unified Composite Score (53.4/100 HOLD vs. KTTA 42.1/100 HOLD), KTTA captures the overall institutional head-to-head verdict (6–4 matrix metrics and 2–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -281.3% operating margin) and revenue trajectory (+1498.1% vs. -15.1% YoY).
- Technical & Structure Timing Caution: KTTA is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.6); meanwhile ENSC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About KTTA vs ENSC
KTTA
Head-to-Head Winner
Pasithea Therapeutics Corp. Common Stock
$0.48
-0.48% 1D
Market Cap
$17.7M
TTM Revenue
$486,559
Forward P/E
N/M
Beta / 30D Vol
0.68β · 185% Vol
Unified Composite Score
42.1
HOLD
Tech 20.0
Fund 40.0
Flow 50.0
Mom 60.0
Weinstein Technical Phase
Distribution · Trim / tighten stop
ENSC
Ensysce Biosciences, Inc. Common Stock
$0.36
-0.17% 1D
Market Cap
$7.0M
TTM Revenue
$4.5M
Forward P/E
0.8x
Beta / 30D Vol
0.98β · 79% Vol
Unified Composite Score
53.4
HOLD
Tech 50.0
Fund 62.0
Flow 50.0
Mom 60.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (KTTA 2 – 2 ENSC)
1. Valuation Multiples
ENSC
Forward P/E
N/M
0.8x
Trailing P/E
N/M
0.8x
PEG Ratio
N/M
N/M
EV / Revenue
36.3x
1.4x
2. Growth & Scale
KTTA
Revenue Growth (YoY)
+1498.1%
-15.1%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$486,559
$4.5M
Market Cap
$17.7M
$7.0M
3. Profitability & Quality
KTTA
Gross Margin
-0.5%
N/A
Operating Margin
0.0%
-281.3%
Net Profit Margin
0.0%
-280.5%
Return on Equity (ROE)
-88.8%
-1295.1%
4. Balance Sheet & Cash Flow
ENSC
Cash Generation (TTM)
-$18M
-$9.7M
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$1.31 Book/Sh · -88.8% ROE
-$499,633 Net Debt
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
Tie
Options Structure Phase
UNCLASSIFIED
UNCLASSIFIED
Current IV / %ile
N/A (N/A)
N/A (N/A)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Distribution
NEUTRAL · Markdown
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: KTTA (6) vs ENSC (4)| Institutional Metric | KTTA | ENSC | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $17.7M | $7.0M | KTTA | |
| Trailing P/E Ratio | N/M | 0.8x | ENSC | |
| Forward P/E Ratio | N/M | 0.8x | ENSC | |
| Revenue Growth (YoY) | +1498.1% | -15.1% | KTTA | |
| Operating Margin (TTM) | 0.0% | -281.3% | KTTA | |
| Net Profit Margin | 0.0% | -280.5% | KTTA | |
| Return on Equity (ROE) | -88.8% | -1295.1% | KTTA | |
| 52-Week Range Position | 11% ($0–$2) | 8% ($0–$2) | KTTA | |
| Beta / 30D Volatility | 0.68β · 185% Vol | 0.98β · 79% Vol | ENSC | |
| Unified Institutional Score | 42.1 / 100 (HOLD) | 53.4 / 100 (HOLD) | ENSC | |
| Trailing 12M Revenue (USD) | $486,559 | $4.5M | Scale | |
| Gross Profit Margin (TTM) | -0.5% | N/A | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 36.3x EV/Rev | N/M PEG · 1.4x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$18M ($1.31 Book/Sh · -88.8% ROE) | -$9.7M (-$499,633 Net Debt) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
KTTA +37.07 pp
3M Horizon
ENSC +4.93 pp
6M Horizon
ENSC +44.58 pp
1Y Horizon
KTTA +80.92 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | KTTA Revenue | ENSC Revenue | KTTA Op. Margin | ENSC Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2020 | N/A | $0M | N/A | -41.0% | ENSC |
| FY2021 | $0M | $0M | -29925.7% | -562.7% | ENSC |
| FY2022 | $0M | $0M | -2587.3% | -959.9% | ENSC |
| FY2023 | N/A | $0M | N/A | -480.5% | ENSC |
| FY2024 | N/A | $10M | N/A | -129.2% | ENSC |
| FY2025 | N/A | $10M | N/A | -202.1% | ENSC |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
KTTA
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact KTTA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
ENSC
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact ENSC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
KTTA Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
ENSC Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ KTTA vs ENSC Key Questions & Quantitative Answers
As of Nov 20, 2026, Pasithea Therapeutics Corp. (KTTA) is the stronger overall head-to-head candidate over Ensysce Biosciences, Inc. (ENSC) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). KTTA carries a Unified Composite Score of 42.1/100 (HOLD) at $0.48 (N/M Forward P/E, 0.0% operating margin), whereas ENSC carries 53.4/100 (HOLD) at $0.36 (0.8x Forward P/E, -281.3% operating margin). Composite vs. Pillar Nuance: While ENSC currently prints a higher short-term Unified Composite Score (53.4/100 HOLD vs. KTTA 42.1/100 HOLD), KTTA captures the overall institutional head-to-head verdict (6–4 matrix metrics and 2–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -281.3% operating margin) and revenue trajectory (+1498.1% vs. -15.1% YoY). Technical & Structure Timing Caution: KTTA is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.6); meanwhile ENSC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
KTTA leads the Growth & Scale pillar: KTTA posts +1498.1% YoY revenue growth and +0.0% YoY earnings growth on $486,559 TTM revenue (-0.5% gross margin, 0.0% operating margin), compared with ENSC at -15.1% YoY revenue growth and +0.0% YoY earnings growth on $4.5M TTM revenue (N/A gross margin, -281.3% operating margin). Across the 6-period historical trajectory (FY2020 to FY2025), KTTA cumulative revenue shifted N/A while ENSC shifted +0.0%. In operating R&D and SG&A reinvestment, KTTA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ENSC.
ENSC screens cheaper on headline valuation multiples. KTTA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 36.3x EV/Revenue (unreported FCF margin), whereas ENSC trades at 0.8x Forward P/E, 0.8x Trailing P/E, N/M PEG, and 1.4x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against KTTA (-88.8% ROE) versus ENSC (-1295.1% ROE) capital efficiency.
In options market volatility and institutional positioning, KTTA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.68β · 185% Vol realized risk). By comparison, ENSC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.98β · 79% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
ENSC vs KTTA · Reverse Pair
KTTA vs QNRX
· Sector Peer
ENSC vs QNRX
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking
VRT vs ETN
· AI Power & Thermal